(84 days)
The AU6 ultrasound imaging system is intended to be used by a physician for diagnostic imaging in cardiac, abdominal, peripheral vessel and fetal applications.
Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
Fetal, Abdominal, Intraoperative (specify) Abdominal, Intraoperative (specify) Peripheral vascular, Intraoperative Neurological, Pediatric, Small Organ (specify), Neonatal Cephalic, Adult Cephalic, Cardiac, Tranesophageal, Transrectal, Transvaginal, Transurethral, Intravascular, Peripheral Vascular, Laparoscopic, Musculo-skeletal Conventional, Musculo-skeletal Superficial, Other - Urological.
Small organs (specifically, thyroid, testicles and breast; Peripheral vascular to include Vein Mapping & Scierotherapy
Ultrasound Imaging System
The Biosound Esaote AU6 Diagnostic Ultrasound System is not an AI/ML device therefore the questions related to acceptance criteria and studies which are relevant to AI/ML devices are not applicable. But, it is a medical device and it has its own set of acceptance criteria and the methods used for the study. I have summarized this information below from the provided text.
Acceptance Criteria and Device Performance:
The device's performance is gauged by whether it can provide diagnostic ultrasound imaging or fluid flow analysis for various clinical applications, either as a "new indication" (N), "previously cleared by FDA" (P), or "added under Appendix E" (E). The specific modes of operation (A, B, M, PWD, CWD, Color Doppler CFM, Amplitude Doppler PD, Color Velocity Imaging) are listed for each clinical application.
| Clinical Application | Mode of Operation (A) | Mode of Operation (B) | Mode of Operation (M) | Mode of Operation (PWD) | Mode of Operation (CWD) | Mode of Operation (CFM) | Mode of Operation (PD) | Mode of Operation (CVI) | Combined (specify) | Other (specify) |
|---|---|---|---|---|---|---|---|---|---|---|
| Fetal | P | P | P | P | P | N/A | B+PW+CFM+M+PD | |||
| Abdominal | P | P | P | P | P | N/A | B+PW+CFM+M+PD | |||
| Intraoperative (Abdominal) | P | P | P | P | P | P | B+PW+CFM+M+PD | |||
| Intraoperative (Peripheral vascular) | E | E | E | E | E | E | B+PW+CFM+M+PD | |||
| Intraoperative Neurological | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Pediatric | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||
| Small Organ (Thyroid, Testicles, Breast) | P | P | P | P | P | P | N/A | B+PW+CFM+M+PD | Vein Mapping & Sclerotherapy | |
| Neonatal Cephalic | P | P | P | P | P | N/A | B+PW+CFM+M+PD | |||
| Adult Cephalic | N | N | N | N | N | N | N | N/A | B+PW+CFM+M+PD | |
| Cardiac | N | N | N | N | N | N | N | N/A | B+PW+CFM+M+PD | |
| Transesophageal | N | N | N | N | N | N | N | N/A | B+PW+CFM+M+PD | |
| Transrectal | N | N | N | N/A | N/A | N | N | N/A | B+PW+CFM+M+PD | |
| Transvaginal | N | N | N | N/A | N/A | N | N | N/A | B+PW+CFM+M+PD | |
| Transurethral | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Intravascular | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Peripheral Vascular | P | P | P | P | P | P | B+PW+CFM+M+PD | Vein Mapping & Sclerotherapy | ||
| Laparoscopic | P | P | P | N/A | N/A | P | P | N/A | B+PW+CFM+M+PD | |
| Musculo-skeletal Conventional | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Musculo-skeletal Superficial | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Other-Urological | N | N | N | N/A | N/A | N | N | N/A | B+PW+CFM+M+PD |
Note: 'A' refers to Annular Array, but in the tables provided for indications, 'A' seems to represent an imaging mode, similar to B, M, PWD, CWD. Given the context of a diagnostic ultrasound system, 'A' likely refers to A-mode imaging, although it's not explicitly defined as such in the provided text. The tables use 'P' for previously cleared by FDA, 'N' for new indication, and 'E' for added under Appendix E.
Study Information (Based on a Traditional Medical Device Clearance):
-
Sample size used for the test set and the data provenance: Not applicable. For a traditional medical device like an ultrasound system, the "test set" in the AI/ML sense (where a predefined dataset is used to evaluate algorithm performance) isn't directly relevant. The evaluation of substantial equivalence typically involves engineering tests, phantom studies, and possibly clinical studies. The document does not specify particular clinical trial data or patient sample sizes. The data provenance is implied to be from the manufacturer (Biosound Esaote) based on their submission to the FDA. The nature of the submission (510(k)) indicates a comparison to a legally marketed predicate device, rather than a de novo submission requiring extensive clinical studies from scratch.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. Ground truth as understood in AI/ML (e.g., expert annotations on images) is not the primary method for evaluating a medical imaging device for 510(k) clearance. The "ground truth" for a device like this would be established through performance specifications, adherence to standards, and comparison to the predicate device's established efficacy and safety.
-
Adjudication method for the test set: Not applicable. Adjudication methods are typically used in clinical trials or for complex image interpretation tasks, which are not detailed in this 510(k) summary for an ultrasound system.
-
If a multi-reader, multi-case (MRMC) comparative effectiveness study was done: Not applicable. MRMC studies are specific to evaluating the diagnostic accuracy of imaging interpretations, often when comparing new AI-assisted workflows to traditional human reading. This document describes a medical imaging device itself, not an AI/ML algorithm that assists human readers.
-
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. The Biosound Esaote AU6 is a diagnostic ultrasound system, not an AI/ML algorithm, and as such, it operates with a human operator. Its performance is inherent to the system's ability to generate images, not as a standalone interpretive algorithm.
-
The type of ground truth used: For a traditional ultrasound system 510(k), the "ground truth" is established through:
- Predicate Device Comparison: The primary method for 510(k) clearance is demonstrating substantial equivalence to a legally marketed predicate device (Esaote AU5, K980468 in this case). This means showing the new device is as safe and effective as the predicate.
- Performance Specifications: The device must meet documented performance specifications for imaging modes, frequencies, transducer types, acoustic output, and other technical characteristics.
- Safety Standards: Compliance with relevant electrical safety and biocompatibility standards.
- Clinical Utility (Implied): The intended uses (cardiac, abdominal, peripheral vessel, fetal) are established categories for which ultrasound is a recognized diagnostic tool. The device is expected to perform within the established clinical utility of such systems.
-
The sample size for the training set: Not applicable. This is not an AI/ML device, so there is no "training set."
-
How the ground truth for the training set was established: Not applicable, as there is no training set for this type of device.
{0}------------------------------------------------
4/30/99
510(k) Summary AU6 Biosound Esaote
K99D360
510(k) Summary
The following safety and effectiveness summary has been prepared pursuant to requirement for 510(k) summaries specified in 21CFR¶807.92(a).
807.92(a)(1)
Submitter Information
Colleen Hittle, Official Correspondent
8000 Castleway Drive
Indianapolis, IN 46250
| Phone: | (317) 849-1916 |
|---|---|
| Facsimile: | (317) 577-9070 |
| Contact Person: | Colleen Hittle |
| Date: | February 3, 1999 |
| 807.92(a)(2) | |
| Trade Name: | AU6 |
| Common Name: | Ultrasound Imaging System |
| Classification Name(s): | System, Imaging, Pulsed Doppler, Ultrasonic |
| Classification Number: | 90IYN; 90IYO |
| 807.92(a)(3) |
Predicate Device(s)
| Esaote | AU5 | K980468 |
|---|---|---|
| -------- | ----- | --------- |
Additional Substantial Equivalence Information is provided in the following substantial Equivalence Comparison Table.
{1}------------------------------------------------
510(k) Summary AU6 Biosound Esaote
807.92(a)(5)
Intended Use(s)
The AU6 ultrasound imaging system is intended to be used by a physician for diagnostic imaging in cardiac, abdominal, peripheral vessel and fetal applications.
{2}------------------------------------------------
| General Characteristics | Esaote | Esaote |
|---|---|---|
| AU5 (K#980468) | AU6 Digital | |
| Transducer Type | Annular Array | Annular Array |
| Mechanical Sector | Mechanical Sector | |
| Linear | Linear | |
| Convex | Convex | |
| Phased Array | Phased Array | |
| NO | 1.5D | |
| 2D Freq MHz | 2.5/15 | 2.5/15 |
| PW Freq MHz | 2.25/10 | 2.25/15 |
| CW Freq MHz | 2.25/5.0 | 2.25/10 |
| 1.5 D | NO | 3.5/10 |
| Imaging Modes | Real-time/2D | Real-time/2D |
| M Mode | M Mode | |
| PW Doppler | PW Doppler | |
| CW Doppler | CW Doppler | |
| CFM Doppler | CFM Doppler | |
| Power Doppler | Power Doppler | |
| Triplex | Triplex | |
| Probes MHz | ||
| Annular Array | 10-20 | 20 |
| Linear | 5.0-13 | 5.0-10.0 |
| Convex | 3.5-7.5 | 3.5-5.0 |
| Phased Array | 2.5-3.5 | 2.5-10 |
| 1.5 D | NO | 3.5-10 |
| Multifreqency probes | Yes | Yes |
| Special probes | IVT transvaginal | IVT transvaginal |
| TRT transrectal | TRT transrectal | |
| TEE transesophageal | ||
| LP laparoscopic | LP laparoscopic | |
| IOE intraoperative | IOE intraoperative | |
| Biopsy attachments | Convex | Convex |
| Linear | Linear | |
| Monitor size (inches) | 14 | 15 |
| Programmability | 6 presets | 10 presets |
| Pulsed/CW Doppler | Yes | Yes |
| HIPRF | No | Yes |
| 2D Updating | Yes | Yes |
| CW steerable | Yes | Yes |
| Audio stereo | Yes | Yes |
| Color Doppler upgrade | Yes | Yes |
| ECG | Option | Option |
| Interconnectivity | NO | YES |
| DSM integrated | YES | YES |
540 mm
690 mm
-height
-depth
Comparison Chart for Substantial Equivalence
1440 mm 1100 mm Page 5
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes representing the three branches of government. The eagle is encircled by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
APR 3 0 1999
Colleen J. Hittle The Anson Group 7992 Castleway Drive Indianapolis, Indiana 46250
Re: K990360 AU6 Diagnostic Ultrasound System Dated: April 9, 1999 Received: April 9, 1999 Regulatory Class: II 21 CFR 892.1550/Procode: 90 IYN
Dear Ms. Hittle:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
This determination of substantial equivalence applies to the following transducers intended for use with the AU6 Diagnostic Ultrasound System as described in your premarket notification:
| Transducer Model Number | |
|---|---|
| CA11 | IOE13A |
| LA13A | LP13A |
| IVT22 | TRT12 |
| SMA50 | PA11B |
| TEE 22 | PT10A |
| P10A |
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic QS inspections, the FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification does not affect any obligation you may have under sections 531 and 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{4}------------------------------------------------
Page -2 - Ms. Hittle:
Please be advised that the determination above is based on the fact that no medical devices have been demonstrated to be safe and effective for in vitro fertilization or percutaneous umbilical blood sampling, nor have any devices been marketed for these uses in interstate commerce prior to May 28, 1976, or reclassified into class I (General Controls) or class II (Special Controls). FDA considers devices specifically intended for in vitro fertilization and percutaneous umbilical blood sampling to be investigational, and subject to the provision of the investigational device exemptions (IDE) regulations, 21 CFR, Part 812. Therefore, your product labeling must be consistent with FDA's position on this use.
This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.
The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:
Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850
This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification' (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
{5}------------------------------------------------
Page -- 3 -- Ms. Hittle
If you have any questions regarding the content of this letter, please contact Rodrigo Perez at (301) 594-1212.
Sincerely yours,
David A. Segerson
for
CAPT Daniel B. Schultz, M.D. Acting Director Division of Reproductive, Abdominal, Ear, Nose and Throat and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
posted on program
(ZAO) noitenkva asirsa 10 mm 1
bined modes: B+PW+CFM+M+PD
K990 360
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Conc ence of CDRH. Office of Device Evaluation (ODE)
09+M+MHC+W9+8 :sabom banidmos ອໄປສະເທດລ
ໃຫ້ສາອຸການປັກອຸລາວປະເທດປະເທດປະເທດປະເທດປະເທດປະເທດປະເທດທີ່ ອງ ສາເງິນທາງ ປີ 18 ທຸລາ ປີ 18 ເປນວັນທີ 1 (ປະເທດ ປາກ ລາວເວ່າລາວ ໄປເພາະປາລະປະເທດລາວ ໄປເພຣິ ລາເອການປະເທດໄປປີ 1 ເປັນເປັນປະຊາ ə xibundda rəpun bəbbə — Ə.Ə.Ə. AQA yq bərmələ — qəsən və qalına ibni mən =N
| Clinical Application | A | B | M | PWD | CWD | Mode of Operation | Combined(specify) | Other(specify) | Mode of Operation | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Color Doppler CFM | Amplitude Doppler PD | Color Velocity Imaging | ClinicalApplication | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | |||||||||
| Ophthalmic | N | N | N | N | N | N | Ophthalmic | ||||||||||||||
| Fetal | N | N | N | N | N | N | Fetal | P | P | P | P | P | Seecomments | ||||||||
| Abdominal | N | N | N | N | N | N | See comments | Abdominal | P | P | P | P | P | Seecomments | |||||||
| Intraoperative (specify)Abdominal | N | N | N | N | N | N | See comments | Intraoperative(specify) | |||||||||||||
| Intraoperative (specify)Peripheral vascular | N | N | N | N | N | N | See comments | IntraoperativeNeurological | |||||||||||||
| IntraoperativeNeurological | N | N | N | N | N | N | See comments | Pediatric | |||||||||||||
| Pediatric | N | N | N | N | N | N | See comments | Small Organ(specify) | |||||||||||||
| Small Organ (specify) | N | N | N | N | N | N | See comments | NeonatalCephalic | P | P | P | P | P | Seecomments | |||||||
| Neonatal Cephalic | N | N | N | N | N | N | See comments | Adult Cephalic | |||||||||||||
| Adult Cephalic | N | N | N | N | N | N | See comments | Cardiac | |||||||||||||
| Cardiac | N | N | N | N | N | N | See comments | Tranesophageal | |||||||||||||
| Transesophageal | N | N | N | N | N | N | See comments | Transrectal | |||||||||||||
| Transrectal | N | N | N | N | N | N | See comments | Transvaginal | |||||||||||||
| Transvaginal | N | N | N | N | N | N | See comments | Transurethral | |||||||||||||
| Transurethral | N | N | N | N | N | N | See comments | Intravascular | |||||||||||||
| Intravascular | N | N | N | N | N | N | See comments | PeripheralVascular | P | P | P | P | P | Seecomments | |||||||
| PeripheralVascular | N | N | N | N | N | N | See comments | Laparoscopic | |||||||||||||
| Laparoscopic | N | N | N | N | N | N | See comments | Musculo-skeletalConventional | |||||||||||||
| Musculo-skeletalConventional | N | N | N | N | N | N | See comments | Musculo-skeletalSuperficial | |||||||||||||
| Musculo-skeletalSuperficial | N | N | N | N | N | N | See comments | Other | |||||||||||||
| Other - Urological | N | N | N | N | N | N | See comments |
q xipuəddə
rash and the more maters bunners and many and the fift ni 107 as 1 101 suoiteribal bauoska)[U 201201361][]
ະຣະບາດ ອາຈາກຈາກປະຈຸບັນ ຈາກປະເທດ wolf birth 10 ອົດເຊີຍແມ່ ນາມປະສາປຸງ ລາວປີ ປະຈຸບັນນາງງາມ
urassag gara
{7}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
David le. Glavon Prescription Use __
(Per 21 CFR 801.109)
{8}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
| Clinical Application | Mode of Operation | Combined (specify) | Other (specify) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | M | PWD | CWD | Color Doppler CFM | Amplitude Doppler PD | Color Velocity Imaging | ||||
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative (specify) Abdominal | P | P | P | P | P | See comments | |||||
| Intraoperative (specify) Peripheral vascular | E | E | E | E | E | See comments | |||||
| Intraoperative Neurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ (specify) | E | E | E | E | E | See comments | |||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| Peripheral Vascular | P | P | P | P | P | See comments | |||||
| Laparoscopic | |||||||||||
| Musculo-skeletal Conventional | |||||||||||
| Musculo-skeletal Superficial | |||||||||||
| Other | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify)Peripheral vascular | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | P | P | P | P | P | P | Seecomments | ||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | E | E | E | E | E | Seecomments | |||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | |||||||||||
| Laparoscopic | P | P | P | P | P | Seecomments | |||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ (specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Transesophageal | |||||||||||
| Transrectal | N | N | N | N | N | Seecomments | |||||
| Transvaginal | N | N | N | N | N | Seecomments | |||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | |||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other-Urological | N | N | N | N | N | Seecomments | |||||
| Mode of Operation | |||||||||||
| ClinicalApplication | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | |||||||||||
| Transrectal | E | E | E | E | E | Seecomments | |||||
| Transvaginal | P | P | P | P | P | Seecomments | |||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | |||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other-Urological | N | N | N | N | N | Seecomments | |||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | P | P | Seecomments | ||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | E | E | Seecomments | ||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | N | N | N | N | N | N | Seecomments | ||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | N | N | N | N | N | N | Seecomments | ||||
| Adult Cephalic | N | N | N | N | N | N | Seecomments | ||||
| Cardiac | N | N | N | N | N | N | Seecomments | ||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | |||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| PediatricSmall Organ(specify)Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | |||||||||||
| Tranesophageal | N | N | N | N | N | N | SeeComments | ||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | |||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventionalMusculo-skeletal | |||||||||||
| SuperficialOther | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | P | ||||||||||
| Cardiac | |||||||||||
| Transesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | E | ||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Mode of Operation | |||||||||||
| Clinical Application | A | B | M | PWD | CWD | ColorDopplerCFM | AmplitudeDopplerPD | ColorVelocityImaging | Combined(specify) | Other(specify) | |
| Ophthalmic | |||||||||||
| Fetal | |||||||||||
| Abdominal | |||||||||||
| Intraoperative(specify) | |||||||||||
| IntraoperativeNeurological | |||||||||||
| Pediatric | |||||||||||
| Small Organ(specify) | |||||||||||
| Neonatal Cephalic | |||||||||||
| Adult Cephalic | |||||||||||
| Cardiac | P | ||||||||||
| Tranesophageal | |||||||||||
| Transrectal | |||||||||||
| Transvaginal | |||||||||||
| Transurethral | |||||||||||
| Intravascular | |||||||||||
| PeripheralVascular | E | ||||||||||
| Laparoscopic | |||||||||||
| Musculo-skeletalConventional | |||||||||||
| Musculo-skeletalSuperficial | |||||||||||
| Other |
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Small organs (specifically, thyroid, testicles and breast; Peripheral vascular to include Vein Mapping & Scierotherapy
Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
| Prescription Use(Per 21 CFR 801.109) | Concurrence of CDRH, Office of Device Evaluation (ODE) | K990360 |
|---|---|---|
| ------------------------------------------ | -------------------------------------------------------- | --------- |
14
{9}------------------------------------------------
AppendixF
Diagnostic Ultrasound Indications for Use Form
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Small Organs (specifically, thyroid, testicles, and beast): Peripheral Vascular to include. Vein Mapping &
Sclerotheragy
Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | K990360 |
|---|---|
| Prescription Use(Per 21 CFR 801.109) |
15
{10}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
ﺎ ﺍﻟﻤﺴﺎﺣﺔ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤﺴﺘﻮﻯ ﺍﻟﻤ
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | ✓ |
|---|---|
| (Per 21 CFR 801.109) |
૧૯
{11}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | |
|---|---|
| (Per 21 CFR 801.109) |
Lezama
{12}------------------------------------------------
Appendix F
TRT12
Diagnostic Ultrasound Indications for Use Form
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Applicable combined modes: B+PW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) 90360
i
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
{13}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Small Organs (specifically, thyroid testicles, and beast): Perigheral vascular to include Yein Mapping & 2018/08/19997
Applicable combined modes: B + M
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Preser (Per 21 CFF R 801.109)
David A. Szezin 19
{14}------------------------------------------------
PA11B
Diagnostic Ultrasound Indications for Use Form
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: : Applicable combined modes: B+PW+CW+CFM+M+PD
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
DE) K990360
- Quind C. Segerson
escription ofe
21 CFR 801.109)
{15}------------------------------------------------
Appendix F
Diagnostic Ultrasound Indications for Use Form
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments: Applicable combined modes: B+PW+CFM+M+PD+CW
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
K99036D
Prescription Use
(Per 21 CFR 801.109) ✓
Daniel A. Szyrm
{16}------------------------------------------------
PT10A
Appendix F
Diagnostic Ultrasound Indications for Use Form
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments:_
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Prescription Use (Per 21 CFR 801.109)
Concurrence of CDRH, Office of Device Evaluation (ODE) K990360
cription Use
21 CFR 801.109)
22
{17}------------------------------------------------
Fill out one form for each ultrasound system and each transducer.
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
N= new indication: P= previously cleared by FDA; E= added under Appendix E
Additional Comments:_
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V (Per 21 CFR 801.109)
23
§ 892.1550 Ultrasonic pulsed doppler imaging system.
(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.